Free Trial
NASDAQ:CRBU

Caribou Biosciences Q1 2026 Earnings Results & Report

Caribou Biosciences logo
$0.37 -0.01 (-1.63%)
As of 12:36 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Caribou Biosciences beat analyst expectations on both earnings and revenue in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$0.26 versus the -$0.33 consensus estimate, while revenue of $2.40 million topped the $2.21 million estimate by $184.00 thousand.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Caribou Biosciences EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.33
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Caribou Biosciences Revenue Results

Actual Revenue
$2.40 million
Expected Revenue
$2.21 million
Beat/Miss
Beat by +$184.00 thousand
YoY Revenue Growth
N/A

Caribou Biosciences Q1 2026 Earnings FAQ

Caribou Biosciences (NASDAQ:CRBU) reported earnings of -$0.26 per share for Q1 2026, beating the consensus estimate of -$0.33. The report was announced on Thursday, May 7, 2026.

Caribou Biosciences reported revenue of $2.40 million for Q1 2026, against a consensus estimate of $2.21 million.

Caribou Biosciences Earnings Headlines

A little-known law has been quietly applied to your savings for years.
Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution, Cede and Company, not the individual investor. If a brokerage collapses and customer securities were pledged as collateral, secured creditors can legally come before account holders. Physical gold held in a self-directed IRA is registered directly to you, with no clearinghouse or central institution holding its title.tc pixel
See More Caribou Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Caribou Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Caribou Biosciences and other key companies, straight to your email.

About Caribou Biosciences

Caribou Biosciences (NASDAQ:CRBU) is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. Its work focuses on allogeneic, or donor-derived, CAR-T cell treatments designed to be manufactured for use by multiple patients.

The company uses its chRDNA genome-editing platform, which combines CRISPR RNA with DNA components, to make targeted changes to cells. Its clinical programs include CAR-T candidates directed at targets such as CD19 and BCMA, which are being developed for certain blood cancers.

Founded in 2011 and based in Berkeley, California, Caribou grew out of research into CRISPR genome-editing technology. Co-founder Rachel Haurwitz serves as the company’s president and chief executive officer.

View Caribou Biosciences Profile